Is an 8‐week regimen of glecaprevir/pibrentasvir sufficient for all #hepatitis C virus infected patients in the real‐world experience?
The revolution of the antiviral treatment of hepatitis C virus (HCV) infection resulting in higher effectiveness came with the introduction of direct‐acting antivirals with pangenotypic regimens as a final touch. Among them, the combination of glecaprevir (GLE) and pibrentasvir (PIB) provides the opportunity for shortening therapy to 8 weeks in the majority of patients. Because of still insufficient evaluation of this regimen in the real‐world … Continue reading Is an 8‐week regimen of glecaprevir/pibrentasvir sufficient for all #hepatitis C virus infected patients in the real‐world experience?